Please assess the completion status of the following clinical trial:

Trial Title: R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated, histologically confirmed mantle cell lymphoma.~* Measurable or evaluable disease.~* All stages are eligible.~* Age \> 18 years.~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.~* Adequate hepatic function:~  * Bilirubin \< 3 mg/dL.~ * Transaminases (SGOT and/or SGPT) \< than 2.5 times the upper limit of normal for the institution, unless due to lymphomatous involvement.~* Serum creatinine \< 1.5 mg/Dl.~* Ability to give informed consent.~* Women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.~* Life expectancy greater than 6 months.~Exclusion Criteria:~* Previous chemotherapy, immunotherapy or radiotherapy for this lymphoma~* Concurrent active malignancies, with the exception of in situ carcinoma of the cervix and basal cell carcinoma of the skin.~* Grade 3 or 4 cardiac failure and/or ejection fraction \< 50.~* Psychological, familial, sociological or geographical conditions that do not permit treatment and/or medical follow-up required to comply with the study protocol.~* Patients with a known history of HIV or AIDS~* Presence of hepatitis or hepatitis B virus (HBV) infection~* Pregnant or breast-feeding women.~* Central nervous system (CNS) involvement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-MACLO-IVAM-T (Type: EXPERIMENTAL): Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).